Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 3

2(25.0%)

Phase 1

2(25.0%)

8Total

Phase 2(4)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03492385Phase 1Completed

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

Role: lead

NCT04286438Phase 3Completed

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Role: lead

NCT03928353Phase 2Completed

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

Role: lead

NCT04122170Phase 2Completed

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

Role: lead

NCT05162131Phase 1Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Role: lead

NCT04969861Phase 2Terminated

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Role: collaborator

NCT03688230Phase 2Withdrawn

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

Role: collaborator

NCT01599754Phase 3Terminated

Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

Role: collaborator

All 8 trials loaded